Skip to main content
SpringerLink
Log in

Detection of Epigenetic Aberrations in the Development of Hepatocellular Carcinoma

  • Protocol
  • First Online:
Book cover Cancer Epigenetics

Part of the book series: Methods in Molecular Biology ((MIMB,volume 1238))

Abstract

Hepatocellular carcinoma (HCC) is the third most common cause of cancer death worldwide. Hepatocarcinogenesis is a complex, multistep process. It is now recognized that HCC is a both genetic and epigenetic disease; genetic and epigenetic components cooperate at all stages of hepatocarcinogenesis. Epigenetic changes involve aberrant DNA methylation, posttranslational histone modifications and aberrant expression of microRNAs all of which can affect the expression of oncogenes, tumor suppressor genes and other tumor-related genes and alter the pathways in cancer development. Several risk factors for HCC, including hepatitis B and C virus infections and exposure to the chemical carcinogen aflatoxin B1 have been found to influence epigenetic changes. Their interactions could play an important role in the initiation and progression of HCC. Discovery and detection of biomarkers for epigenetic changes is a promising area for early diagnosis and risk prediction of HCC.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Schafer DF, Sorrell MF (1999) Hepatocellular carcinoma. Lancet 353:1253–1257

    CAS  PubMed  Google Scholar 

  2. Center MM, Jemal A (2011) International trends in liver cancer incidence rates. Cancer Epidemiol Biomarkers Prev 20:2362–2368

    PubMed  Google Scholar 

  3. El-Serag HB, Mason AC (1999) Rising incidence of hepatocellular carcinoma in the United States. New Engl J Med 340:745–750

    CAS  PubMed  Google Scholar 

  4. Chen CJ, Yu MW, Liaw YF (1997) Epidemiologic characteristics and risk factors of hepatocellular carcinoma. J Gastroenterol Hepatol 12:S294–S308

    CAS  PubMed  Google Scholar 

  5. Chen SY, Wang LY, Lunn R, Tsai WY, Lee PH, Lee CS et al (2002) Polycyclic aromatic hydrocarbon-DNA adducts in liver tissues of hepatocellular carcinoma patients and controls. Int J Cancer 99:14–21

    CAS  PubMed  Google Scholar 

  6. Santella RM, Zhang YJ, Hsieh LL, Young TL, Lu XQ, Lee BM et al (1991) Immunological methods for monitoring human expsoure to benzo[a]pyrene and aflatoxin B1: measurement of carcinogen adducts. In: Vanderlaan M (ed) Immunoassays for Monitoring human exposure to toxic chemicals. ACS Publications, Washington, DC, pp 229–245

    Google Scholar 

  7. Herath NI, Leggett BA, MacDonald GA (2006) Review of genetic and epigenetic alterations in hepatocarcinogenesis. J Gastroenterol Hepatol 21:15–21

    CAS  PubMed  Google Scholar 

  8. Thorgeirsson SS, Grisham JW (2002) Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 31:339–346

    CAS  PubMed  Google Scholar 

  9. Baylin SB, Herma JG (2000) DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet 16:168–174

    CAS  PubMed  Google Scholar 

  10. Jones PA, Laird PW (1999) Cancer epigenetics comes of age. Nat Genet 21:163–167

    CAS  PubMed  Google Scholar 

  11. Calvisi DF, Ladu S, Gorden A, Farina M, Lee JS, Conner EA et al (2007) Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma. J Clin Invest 117:2713–2722

    CAS  PubMed Central  PubMed  Google Scholar 

  12. Nishida N, Goel A (2011) Genetic and epigenetic signatures in human hepatocellular carcinoma: a systematic review. Curr Genomics 12:130–137

    CAS  PubMed Central  PubMed  Google Scholar 

  13. Baylin SB (2005) DNA methylation and gene silencing in cancer. Nat Clin Pract Oncol 2(Suppl 1):S4–S11

    CAS  PubMed  Google Scholar 

  14. Herceg Z (2007) Epigenetics and cancer: towards an evaluation of the impact of environmental and dietary factors. Mutagenesis 22:91–103

    CAS  PubMed  Google Scholar 

  15. Yang JD, Roberts LR (2010) Epidemiology and management of hepatocellular carcinoma. Infect Dis Clin North Am 24:899–919, viii

    CAS  PubMed Central  PubMed  Google Scholar 

  16. Libbrecht L, Desmet V, Roskams T (2005) Preneoplastic lesions in human hepatocarcinogenesis. Liver Int 25:16–27

    CAS  PubMed  Google Scholar 

  17. Esteller M, Corn PG, Baylin SB, Herman JG (2001) A gene hypermethylation profile of human cancer. Cancer Res 61:3225–3229

    CAS  PubMed  Google Scholar 

  18. Jones PA, Baylin SB (2002) The fundamental role of epigenetic events in cancer. Nat Rev Genet 3:415–428

    CAS  PubMed  Google Scholar 

  19. Irizarry RA, Ladd-Acosta C, Wen B, Wu Z, Montano C, Onyango P et al (2009) The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores. Nat Genet 41:178–186

    CAS  PubMed Central  PubMed  Google Scholar 

  20. Rakyan VK, Down TA, Balding DJ, Beck S (2011) Epigenome-wide association studies for common human diseases. Nat Rev Genet 12:529–541

    CAS  PubMed Central  PubMed  Google Scholar 

  21. Matsuzaki K, Deng G, Tanaka H, Kakar S, Miura S, Kim YS (2005) The relationship between global methylation level, loss of heterozygosity, and microsatellite instability in sporadic colorectal cancer. Clin Cancer Res 11:8564–8569

    CAS  PubMed  Google Scholar 

  22. Toyota M, Issa JP (2005) Epigenetic changes in solid and hematopoietic tumors. Semin Oncol 32:521–530

    CAS  PubMed  Google Scholar 

  23. Chan AO, Rashid A (2006) CpG island methylation in precursors of gastrointestinal malignancies. Curr Mol Med 6:401–408

    CAS  PubMed  Google Scholar 

  24. Zhang YJ, Ahsan H, Chen Y, Lunn RM, Wang LY, Chen SY et al (2002) High frequency of promoter hypermethylation of the RASSF1A and p16 genes and its relationship to aflatoxin B1-DNA adducts level in human hepatocellular carcinoma. Mol Carcinogenesis 35:85–92

    CAS  Google Scholar 

  25. Liew CT, Li HM, Lo KW, Leow CK, Chan JY, Hin LY et al (1999) High frequency of p16INK4A gene alterations in hepatocellular carcinoma. Oncogene 18:789–795

    CAS  PubMed  Google Scholar 

  26. Wong IH, Lo YM, Zhang J, Liew CT, Ng MH, Wong N et al (1999) Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients. Cancer Res 59:71–73

    CAS  PubMed  Google Scholar 

  27. Herman JG, Civin CI, Issa JP, Collector MI, Sharkis SJ, Baylin SB (1997) Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies. Cancer Res 57:837–841

    CAS  PubMed  Google Scholar 

  28. Wong IH, Lo YM, Yeo W, Lau WY, Johnson PJ (2000) Frequent p15 promoter methylation in tumor and peripheral blood from hepatocellular carcinoma patients. Clin Cancer Res 6:3516–3521

    CAS  PubMed  Google Scholar 

  29. Edamoto Y, Hara A, Biernat W, Terracciano L, Cathomas G, Riehle HM et al (2003) Alterations of RB1, p53 and Wnt pathways in hepatocellular carcinomas associated with hepatitis C, hepatitis B and alcoholic liver cirrhosis. Int J Cancer 106:334–341

    CAS  PubMed  Google Scholar 

  30. Zhong S, Tang MW, Yeo W, Liu C, Lo YM, Johnson PJ (2002) Silencing of GSTP1 gene by CpG island DNA hypermethylation in HBV-associated hepatocellular carcinomas. Clin Cancer Res 8:1087–1092

    CAS  PubMed  Google Scholar 

  31. Zhang YJ, Chen Y, Ahsan H, Lunn RM, Chen SY, Lee PH et al (2005) Silencing of glutathione S-transferase P1 by promoter hypermethylation and its relationship to environmental chemical carcinogens in hepatocellular carcinoma. Cancer Lett 221:135–143

    CAS  PubMed  Google Scholar 

  32. Okochi O, Hibi K, Sakai M, Inoue S, Takeda S, Kaneko T et al (2003) Methylation-mediated silencing of SOCS-1 gene in hepatocellular carcinoma derived from cirrhosis. Clin Cancer Res 9:5295–5298

    CAS  PubMed  Google Scholar 

  33. Yang B, Guo M, Herman JG, Clark DP (2003) Aberrant promoter methylation profiles of tumor suppressor genes in hepatocellular carcinoma. Am J Pathol 163:1101–1107

    CAS  PubMed Central  PubMed  Google Scholar 

  34. Zhang YJ, Wu HC, Shen J, Li H, Wang L, Yu MW et al (2009) Silencing of Hint1, a novel tumor suppressor gene, by promoter hypermethylation in hepatocellular carcinoma. Cancer Lett 275:277–284

    CAS  PubMed Central  PubMed  Google Scholar 

  35. Niwa Y, Kanda H, Shikauchi Y, Saiura A, Matsubara K, Kitagawa T et al (2005) Methylation silencing of SOCS-3 promotes cell growth and migration by enhancing JAK/STAT and FAK signalings in human hepatocellular carcinoma. Oncogene 24:6406–6417

    CAS  PubMed  Google Scholar 

  36. Piao GH, Piao WH, He Y, Zhang HH, Wang GQ, Piao Z (2008) Hyper-methylation of RIZ1 tumor suppressor gene is involved in the early tumorigenesis of hepatocellular carcinoma. Histol Histopathol 23:1171–1175

    CAS  PubMed  Google Scholar 

  37. Zhang YJ, Chen Y, Ahsan H, Lunn RM, Lee PH, Chen CJ et al (2003) Inactivation of the DNA repair gene O-6-methylguanine-DNA methyltransferase by promoter hypermethylation and its relationship to aflatoxin B-1-DNA adducts and p53 mutation in hepatocellular carcinoma. Int J Cancer 103:440–444

    CAS  PubMed  Google Scholar 

  38. Herceg Z, Paliwal A (2011) Epigenetic mechanisms in hepatocellular carcinoma: how environmental factors influence the epigenome. Mutat Res 727:55–61

    CAS  PubMed  Google Scholar 

  39. Zhong S, Yeo W, Tang M, Wong N, Johnson PJ (2002) Intensive hypermethylation of the CpG island of Ras Association Domain Family 1A (RASSF1A) in HBV-associated heptocellular carcinoma abstract #5578. Proc Am Assoc Cancer Res 43:1125–1126

    Google Scholar 

  40. Jicai Z, Zongtao Y, Jun L, Haiping L, Jianmin W, Lihua H (2006) Persistent infection of hepatitis B virus is involved in high rate of p16 methylation in hepatocellular carcinoma. Mol Carcinog 45:530–536

    PubMed  Google Scholar 

  41. Zhu R, Li BZ, Li H, Ling YQ, Hu XQ, Zhai WR et al (2007) Association of p16INK4A hypermethylation with hepatitis B virus X protein expression in the early stage of HBV-associated hepatocarcinogenesis. Pathol Int 57:328–336

    CAS  PubMed  Google Scholar 

  42. Feng QHS, Das T, Huang J, Feng Z, Gretch D (2013) Epigenetic mechanisms in hepatitis C virus-associated hepatocellular carcinoma: a potential new link between stem cells, virology and cancer. Am Med J 4:21–35

    Google Scholar 

  43. Lambert MP, Paliwal A, Vaissiere T, Chemin I, Zoulim F, Tommasino M et al (2011) Aberrant DNA methylation distinguishes hepatocellular carcinoma associated with HBV and HCV infection and alcohol intake. J Hepatol 54:705–715

    CAS  PubMed  Google Scholar 

  44. Lunn RM, Zhang YJ, Wang LY, Chen CJ, Lee PH, Lee CS et al (1997) p53 Mutations, chronic hepatitis B virus infection, and aflatoxin exposure in hepatocellular carcinoma in Taiwan. Cancer Res 57:3471–3477

    CAS  PubMed  Google Scholar 

  45. Zhang YJ, Rossner P, Chen Y, Agrawal M, Wang Q, Wang L et al (2006) Aflatoxin B1 and polycyclic aromatic hydrocarbon adducts, p53 mutations and p16 methylation in liver tissue and plasma of hepatocellular carcinoma patients. Int J Cancer 119:985–991

    CAS  PubMed  Google Scholar 

  46. Baylin SB, Ohm JE (2006) Epigenetic gene silencing in cancer – a mechanism for early oncogenic pathway addiction? Nat Rev Cancer 6:107–116

    CAS  PubMed  Google Scholar 

  47. Rivenbark AG, Coleman WB (2007) The use of epigenetic biomarkers for preclinical detection of hepatocellular carcinoma: potential for noninvasive screening of high-risk populations. Clin Cancer Res 13:2309–2312

    CAS  PubMed  Google Scholar 

  48. Zhang YJ, Wu HC, Shen J, Ahsan H, Tsai WY, Yang HI et al (2007) Predicting hepatocellular carcinoma by detection of aberrant promoter methylation in serum DNA. Clin Cancer Res 13:2378–2384

    CAS  PubMed  Google Scholar 

  49. Rollins RA, Haghighi F, Edwards JR, Das R, Zhang MQ, Ju J et al (2006) Large-scale structure of genomic methylation patterns. Genome Res 16:157–163

    CAS  PubMed Central  PubMed  Google Scholar 

  50. Das R, Dimitrova N, Xuan Z, Rollins RA, Haghighi F, Edwards JR et al (2006) Computational prediction of methylation status in human genomic sequences. Proc Natl Acad Sci U S A 103:10713–10716

    CAS  PubMed Central  PubMed  Google Scholar 

  51. Fouse SD, Nagarajan RO, Costello JF (2010) Genome-scale DNA methylation analysis. Epigenomics 2:105–117

    CAS  PubMed Central  PubMed  Google Scholar 

  52. Bibikova M, Fan JB (2009) GoldenGate(R) assay for DNA methylation profiling. Methods Mol Biol 507:149–163

    CAS  PubMed  Google Scholar 

  53. Ammerpohl O, Pratschke J, Schafmayer C, Haake A, Faber W, von Kampen O et al (2012) Distinct DNA methylation patterns in cirrhotic liver and hepatocellular carcinoma. Int J Cancer 130:1319–1328

    CAS  PubMed  Google Scholar 

  54. Gao W, Kondo Y, Shen L, Shimizu Y, Sano T, Yamao K et al (2008) Variable DNA methylation patterns associated with progression of disease in hepatocellular carcinomas. Carcinogenesis 29:1901–1910

    CAS  PubMed  Google Scholar 

  55. Shitani M, Sasaki S, Akutsu N, Takagi H, Suzuki H, Nojima M et al (2012) Genome-wide analysis of DNA methylation identifies novel cancer-related genes in hepatocellular carcinoma. Tumour Biol 33 [Epub ahead of print]

    Google Scholar 

  56. Shin SH, Kim BH, Jang JJ, Suh KS, Kang GH (2010) Identification of novel methylation markers in hepatocellular carcinoma using a methylation array. J Korean Med Sci 25:1152–1159

    CAS  PubMed Central  PubMed  Google Scholar 

  57. Hernandez-Vargas H, Lambert MP, Calvez-Kelm F, Gouysse G, McKay-Chopin S, Tavtigian SV et al (2010) Hepatocellular carcinoma displays distinct DNA methylation signatures with potential as clinical predictors. PLoS One 5:e9749

    PubMed Central  PubMed  Google Scholar 

  58. Archer KJ, Mas VR, Maluf DG, Fisher RA (2010) High-throughput assessment of CpG site methylation for distinguishing between HCV-cirrhosis and HCV-associated hepatocellular carcinoma. Mol Genet Genomics 283:341–349

    CAS  PubMed Central  PubMed  Google Scholar 

  59. Shen L, Kondo Y, Guo Y, Zhang J, Zhang L, Ahmed S et al (2007) Genome-wide profiling of DNA methylation reveals a class of normally methylated CpG island promoters. PLoS Genet 3:2023–2036

    CAS  PubMed  Google Scholar 

  60. Shen J, Wang S, Zhang YJ, Wu HC, Kibriya MG, Jasmine F et al (2013) Exploring genome-wide DNA methylation profiles altered in hepatocellular carcinoma using Infinium HumanMethylation 450 BeadChips. Epigenetics 8:34–43

    CAS  PubMed Central  PubMed  Google Scholar 

  61. Revill K, Wang T, Lachenmayer A, Kojima K, Harrington A, Li J et al (2013) Genome-wide methylation analysis and epigenetic unmasking identify tumor suppressor genes in hepatocellular carcinoma. Gastroenterology 145:1424–1435

    CAS  PubMed  Google Scholar 

  62. Tao R, Li J, Xin J, Wu J, Guo J, Zhang L et al (2011) Methylation profile of single hepatocytes derived from hepatitis B virus-related hepatocellular carcinoma. PLoS One 6:e19862

    CAS  PubMed Central  PubMed  Google Scholar 

  63. Lin CH, Hsieh SY, Sheen IS, Lee WC, Chen TC, Shyu WC et al (2001) Genome-wide hypomethylation in hepatocellular carcinogenesis. Cancer Res 61:4238–4243

    CAS  PubMed  Google Scholar 

  64. Wilson AS, Power BE, Molloy PL (2007) DNA hypomethylation and human diseases. Biochimica et Biophysica Acta (BBA) Rev Cancer 1775:138–162

    CAS  Google Scholar 

  65. Jeanpierre M (1994) Human satellites 2 and 3. Ann Genet 37:163–171

    CAS  PubMed  Google Scholar 

  66. Ehrlich M (2002) DNA methylation in cancer: too much, but also too little. Oncogene 21:5400–5413

    CAS  PubMed  Google Scholar 

  67. Ushijima T, Morimura K, Hosoya Y, Okonogi H, Tatematsu M, Sugimura T et al (1997) Establishment of methylation-sensitive-representational difference analysis and isolation of hypo- and hypermethylated genomic fragments in mouse liver tumors. Proc Natl Acad Sci U S A 94:2284–2289

    CAS  PubMed Central  PubMed  Google Scholar 

  68. Kim MJ, White-Cross JA, Shen L, Issa JP, Rashid A (2009) Hypomethylation of long interspersed nuclear element-1 in hepatocellular carcinomas. Mod Pathol 22:442–449

    CAS  PubMed  Google Scholar 

  69. Takai D, Yagi Y, Habib N, Sugimura T, Ushijima T (2000) Hypomethylation of LINE1 retrotransposon in human hepatocellular carcinomas, but not in surrounding liver cirrhosis. Jpn J Clin Oncol 30:306–309

    CAS  PubMed  Google Scholar 

  70. Calvisi DF, Simile MM, Ladu S, Pellegrino R, De Murtas V, Pinna F et al (2007) Altered methionine metabolism and global DNA methylation in liver cancer: relationship with genomic instability and prognosis. Int J Cancer 121:2410–2420

    CAS  PubMed  Google Scholar 

  71. Lee H, Kim BH, Cho NY, Yoo EJ, Choi M, Shin S et al (2009) Prognostic implications of and relationship between CpG island hypermethylation and repetitive DNA hypomethylation in hepatocellular carcinoma. Clin Cancer Res 15:812–820

    CAS  PubMed  Google Scholar 

  72. Lee JO, Kwun HJ, Jung JK, Choi KH, Min DS, Jang KL (2005) Hepatitis B virus X protein represses E-cadherin expression via activation of DNA methyltransferase 1. Oncogene 24:6617–6625

    CAS  PubMed  Google Scholar 

  73. Park IY, Sohn BH, Yu E, Suh DJ, Chung YH, Lee JH et al (2007) Aberrant epigenetic modifications in hepatocarcinogenesis induced by hepatitis B virus X protein. Gastroenterology 132:1476–1494

    CAS  PubMed  Google Scholar 

  74. Zhang YJ, Wu HC, Yazici H, Yu MW, Lee PH, Santella RM (2012) Global hypomethylation in hepatocellular carcinoma and its relationship to aflatoxin B(1) exposure. World J Hepatol 4:169–175

    CAS  PubMed Central  PubMed  Google Scholar 

  75. Gao Y, Baccarelli A, Shu XO, Ji BT, Yu K, Tarantini L et al (2012) Blood leukocyte Alu and LINE-1 methylation and gastric cancer risk in the Shanghai Women’s Health Study. Br J Cancer 106:585–591

    CAS  PubMed Central  PubMed  Google Scholar 

  76. Zhu ZZ, Sparrow D, Hou L, Tarantini L, Bollati V, Litonjua AA et al (2011) Repetitive element hypomethylation in blood leukocyte DNA and cancer incidence, prevalence, and mortality in elderly individuals: the Normative Aging Study. Cancer Causes Control 22:437–447

    PubMed Central  PubMed  Google Scholar 

  77. Wu HC, Wang Q, Yang HI, Tsai WY, Chen CJ, Santella RM (2012) Global DNA methylation levels in white blood cells as a biomarker for hepatocellular carcinoma risk: a nested case-control study. Carcinogenesis 33:1340–1345

    CAS  PubMed Central  PubMed  Google Scholar 

  78. Stefanska B, Huang J, Bhattacharyya B, Suderman M, Hallett M, Han ZG et al (2011) Definition of the landscape of promoter DNA hypomethylation in liver cancer. Cancer Res 71:5891–5903

    CAS  PubMed  Google Scholar 

  79. Kong LM, Liao CG, Chen L, Yang HS, Zhang SH, Zhang Z et al (2011) Promoter hypomethylation up-regulates CD147 expression through increasing Sp1 binding and associates with poor prognosis in human hepatocellular carcinoma. J Cell Mol Med 15:1415–1428

    CAS  PubMed  Google Scholar 

  80. Ribieras S, Lefebvre O, Tomasetto C, Rio MC (2001) Mouse Trefoil factor genes: genomic organization, sequences and methylation analyses. Gene 266:67–75

    CAS  PubMed  Google Scholar 

  81. Okada H, Kimura MT, Tan D, Fujiwara K, Igarashi J, Makuuchi M et al (2005) Frequent trefoil factor 3 (TFF3) overexpression and promoter hypomethylation in mouse and human hepatocellular carcinomas. Int J Oncol 26:369–377

    CAS  PubMed Central  PubMed  Google Scholar 

  82. Zhao W, Liu H, Liu W, Wu Y, Chen W, Jiang B et al (2006) Abnormal activation of the synuclein-gamma gene in hepatocellular carcinomas by epigenetic alteration. Int J Oncol 28:1081–1088

    CAS  PubMed  Google Scholar 

  83. Pogribny IP, Rusyn I (2014) Role of epigenetic aberrations in the development and progression of human hepatocellular carcinoma. Cancer Lett 342:223–230

    CAS  PubMed Central  PubMed  Google Scholar 

  84. Song MA, Tiirikainen M, Kwee S, Okimoto G, Yu H, Wong LL (2013) Elucidating the landscape of aberrant DNA methylation in hepatocellular carcinoma. PLoS One 8:e55761

    CAS  PubMed Central  PubMed  Google Scholar 

  85. Chen T, Li E (2004) Structure and function of eukaryotic DNA methyltransferases. Curr Top Dev Biol 60:55–89

    CAS  PubMed  Google Scholar 

  86. Goll MG, Bestor TH (2005) Eukaryotic cytosine methyltransferases. Annu Rev Biochem 74:481–514

    CAS  PubMed  Google Scholar 

  87. Hermann A, Schmitt S, Jeltsch A (2003) The human Dnmt2 has residual DNA-(cytosine-C5) methyltransferase activity. J Biol Chem 278:31717–31721

    CAS  PubMed  Google Scholar 

  88. Goll MG, Kirpekar F, Maggert KA, Yoder JA, Hsieh CL, Zhang X et al (2006) Methylation of tRNAAsp by the DNA methyltransferase homolog Dnmt2. Science 311:395–398

    CAS  PubMed  Google Scholar 

  89. Robertson KD (2001) DNA methylation, methyltransferases, and cancer. Oncogene 20:3139–3155

    CAS  PubMed  Google Scholar 

  90. Robertson KD, Uzvolgyi E, Liang G, Talmadge C, Sumegi J, Gonzales FA et al (1999) The human DNA methyltransferases (DNMTs) 1, 3a and 3b: coordinate mRNA expression in normal tissues and overexpression in tumors. Nucleic Acids Res 27:2291–2298

    CAS  PubMed Central  PubMed  Google Scholar 

  91. Kanai Y, Ushijima S, Hui AM, Ochiai A, Tsuda H, Sakamoto M et al (1997) The E-cadherin gene is silenced by CpG methylation in human hepatocellular carcinomas. Int J Cancer 71:355–359

    CAS  PubMed  Google Scholar 

  92. Saito Y, Kanai Y, Sakamoto M, Saito H, Ishii H, Hirohashi S (2001) Expression of mRNA for DNA methyltransferases and methyl-CpG-binding proteins and DNA methylation status on CpG islands and pericentromeric satellite regions during human hepatocarcinogenesis. Hepatology 33:561–568

    CAS  PubMed  Google Scholar 

  93. Choi MS, Shim YH, Hwa JY, Lee SK, Ro JY, Kim JS et al (2003) Expression of DNA methyltransferases in multistep hepatocarcinogenesis. Hum Pathol 34:11–17

    CAS  PubMed  Google Scholar 

  94. Park HJ, Yu E, Shim YH (2006) DNA methyltransferase expression and DNA hypermethylation in human hepatocellular carcinoma. Cancer Lett 233:271–278

    CAS  PubMed  Google Scholar 

  95. Saito Y, Kanai Y, Nakagawa T, Sakamoto M, Saito H, Ishii H et al (2003) Increased protein expression of DNA methyltransferase (DNMT) 1 is significantly correlated with the malignant potential and poor prognosis of human hepatocellular carcinomas. Int J Cancer 105:527–532

    CAS  PubMed  Google Scholar 

  96. Oh BK, Kim H, Park HJ, Shim YH, Choi J, Park C et al (2007) DNA methyltransferase expression and DNA methylation in human hepatocellular carcinoma and their clinicopathological correlation. Int J Mol Med 20:65–73

    CAS  PubMed  Google Scholar 

  97. Jung JK, Arora P, Pagano JS, Jang KL (2007) Expression of DNA methyltransferase 1 is activated by hepatitis B virus X protein via a regulatory circuit involving the p16INK4a-cyclin D1-CDK 4/6-pRb-E2F1 pathway. Cancer Res 67:5771–5778

    CAS  PubMed  Google Scholar 

  98. Zheng DL, Zhang L, Cheng N, Xu X, Deng Q, Teng XM et al (2009) Epigenetic modification induced by hepatitis B virus X protein via interaction with de novo DNA methyltransferase DNMT3A. J Hepatol 50:377–387

    CAS  PubMed  Google Scholar 

  99. Arora P, Kim EO, Jung JK, Jang KL (2008) Hepatitis C virus core protein downregulates E-cadherin expression via activation of DNA methyltransferase 1 and 3b. Cancer Lett 261:244–252

    CAS  PubMed  Google Scholar 

  100. Kouzarides T (2007) Chromatin modifications and their function. Cell 128:693–705

    CAS  PubMed  Google Scholar 

  101. Schneider R, Grosschedl R (2007) Dynamics and interplay of nuclear architecture, genome organization, and gene expression. Genes Dev 21:3027–3043

    CAS  PubMed  Google Scholar 

  102. Creyghton MP, Cheng AW, Welstead GG, Kooistra T, Carey BW, Steine EJ et al (2010) Histone H3K27ac separates active from poised enhancers and predicts developmental state. Proc Natl Acad Sci U S A 107:21931–21936

    CAS  PubMed Central  PubMed  Google Scholar 

  103. He C, Xu J, Zhang J, Xie D, Ye H, Xiao Z et al (2012) High expression of trimethylated histone H3 lysine 4 is associated with poor prognosis in hepatocellular carcinoma. Hum Pathol 43:1425–1435

    CAS  PubMed  Google Scholar 

  104. Cai MY, Hou JH, Rao HL, Luo RZ, Li M, Pei XQ et al (2011) High expression of H3K27me3 in human hepatocellular carcinomas correlates closely with vascular invasion and predicts worse prognosis in patients. Mol Med 17:12–20

    CAS  PubMed Central  PubMed  Google Scholar 

  105. Kondo Y, Shen L, Suzuki S, Kurokawa T, Masuko K, Tanaka Y et al (2007) Alterations of DNA methylation and histone modifications contribute to gene silencing in hepatocellular carcinomas. Hepatol Res 37:974–983

    CAS  PubMed  Google Scholar 

  106. Yao JY, Zhang L, Zhang X, He ZY, Ma Y, Hui LJ et al (2010) H3K27 trimethylation is an early epigenetic event of p16INK4a silencing for regaining tumorigenesis in fusion reprogrammed hepatoma cells. J Biol Chem 285:18828–18837

    CAS  PubMed Central  PubMed  Google Scholar 

  107. Zhang C, Li H, Wang Y, Liu W, Zhang Q, Zhang T et al (2010) Epigenetic inactivation of the tumor suppressor gene RIZ1 in hepatocellular carcinoma involves both DNA methylation and histone modifications. J Hepatol 53:889–895

    CAS  PubMed  Google Scholar 

  108. Sistayanarain A, Tsuneyama K, Zheng H, Takahashi H, Nomoto K, Cheng C et al (2006) Expression of Aurora-B kinase and phosphorylated histone H3 in hepatocellular carcinoma. Anticancer Res 26:3585–3593

    CAS  PubMed  Google Scholar 

  109. Pote N, Alexandrov T, Le Faouder J, Laouirem S, Leger T, Mebarki M et al (2013) Imaging mass spectrometry reveals modified forms of histone H4 as new biomarkers of microvascular invasion in hepatocellular carcinomas. Hepatology 58:983–994

    CAS  PubMed  Google Scholar 

  110. Sharma S, Kelly TK, Jones PA (2010) Epigenetics in cancer. Carcinogenesis 31:27–36

    CAS  PubMed Central  PubMed  Google Scholar 

  111. Hamamoto R, Furukawa Y, Morita M, Iimura Y, Silva FP, Li M et al (2004) SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells. Nat Cell Biol 6:731–740

    CAS  PubMed  Google Scholar 

  112. Wu LM, Yang Z, Zhou L, Zhang F, Xie HY, Feng XW et al (2010) Identification of histone deacetylase 3 as a biomarker for tumor recurrence following liver transplantation in HBV-associated hepatocellular carcinoma. PLoS One 5:e14460

    CAS  PubMed Central  PubMed  Google Scholar 

  113. Choi HN, Bae JS, Jamiyandorj U, Noh SJ, Park HS, Jang KY et al (2011) Expression and role of SIRT1 in hepatocellular carcinoma. Oncol Rep 26:503–510

    CAS  PubMed  Google Scholar 

  114. Cheng AS, Lau SS, Chen Y, Kondo Y, Li MS, Feng H et al (2011) EZH2-mediated concordant repression of Wnt antagonists promotes beta-catenin-dependent hepatocarcinogenesis. Cancer Res 71:4028–4039

    CAS  PubMed  Google Scholar 

  115. Bhaskara S, Knutson SK, Jiang G, Chandrasekharan MB, Wilson AJ, Zheng S et al (2010) Hdac3 is essential for the maintenance of chromatin structure and genome stability. Cancer Cell 18:436–447

    CAS  PubMed Central  PubMed  Google Scholar 

  116. Yang L, Ren J, He J, Chen LB (2009) Induction of SMYD3 by hepatitis B virus X gene in HepG2 cells. Zhonghua Gan ZangBingZa Zhi 17:297–300

    CAS  Google Scholar 

  117. Ambros V (2004) The functions of animal microRNAs. Nature 431:350–355

    CAS  PubMed  Google Scholar 

  118. Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116:281–297

    CAS  PubMed  Google Scholar 

  119. de Juan C, Iniesta P, Vega FJ, Peinado MA, Fernandez C, Caldes T et al (1998) Prognostic value of genomic damage in non-small-cell lung cancer. Br J Cancer 77:1971–1977

    PubMed Central  PubMed  Google Scholar 

  120. Saito Y, Hibino S, Saito H (2014) Alterations of epigenetics and microRNA in hepatocellular carcinoma. Hepatol Res 44:31–42

    Google Scholar 

  121. Valeri N, Vannini I, Fanini F, Calore F, Adair B, Fabbri M (2009) Epigenetics, miRNAs, and human cancer: a new chapter in human gene regulation. Mamm Genome 20:573–580

    CAS  PubMed  Google Scholar 

  122. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S et al (2004) Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A 101:2999–3004

    CAS  PubMed Central  PubMed  Google Scholar 

  123. Negrini M, Gramantieri L, Sabbioni S, Croce CM (2011) microRNA involvement in hepatocellular carcinoma. Anticancer Agents Med Chem 11:500–521

    CAS  PubMed  Google Scholar 

  124. Callegari E, Elamin BK, Sabbioni S, Gramantieri L, Negrini M (2013) Role of microRNAs in hepatocellular carcinoma: a clinical perspective. Onco Targets Ther 6:1167–1178

    PubMed Central  PubMed  Google Scholar 

  125. Fornari F, Gramantieri L, Ferracin M, Veronese A, Sabbioni S, Calin GA et al (2008) MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. Oncogene 27:5651–5661

    CAS  PubMed  Google Scholar 

  126. Garofalo M, Di Leva G, Romano G, Nuovo G, Suh SS, Ngankeu A et al (2009) miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell 16:498–509

    CAS  PubMed Central  PubMed  Google Scholar 

  127. Ko K, Peng H, Tang H, Cho ME, Peng J, Aller MA, Yang P (2012) Recent advances of miRNAinvolvement in hepatocellular carcinoma and cholangiocarcinoma. Open J Intern Med 2:135–162

    Google Scholar 

  128. Ji J, Shi J, Budhu A, Yu Z, Forgues M, Roessler S et al (2009) MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med 361:1437–1447

    CAS  PubMed Central  PubMed  Google Scholar 

  129. Viswanathan SR, Powers JT, Einhorn W, Hoshida Y, Ng TL, Toffanin S et al (2009) Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet 41:843–848

    CAS  PubMed Central  PubMed  Google Scholar 

  130. Fornari F, Milazzo M, Chieco P, Negrini M, Calin GA, Grazi GL et al (2010) MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res 70:5184–5193

    CAS  PubMed  Google Scholar 

  131. Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T (2007) MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 133:647–658

    CAS  PubMed  Google Scholar 

  132. Han ZB, Chen HY, Fan JW, Wu JY, Tang HM, Peng ZH (2012) Up-regulation of microRNA-155 promotes cancer cell invasion and predicts poor survival of hepatocellular carcinoma following liver transplantation. J Cancer Res Clin Oncol 138:153–161

    CAS  PubMed  Google Scholar 

  133. Chen L, Jiang M, Yuan W, Tang H (2012) miR-17-5p as a novel prognostic marker for hepatocellular carcinoma. J Invest Surg 25:156–161

    PubMed  Google Scholar 

  134. Elyakim E, Sitbon E, Faerman A, Tabak S, Montia E, Belanis L et al (2010) hsa-miR-191 is a candidate oncogene target for hepatocellular carcinoma therapy. Cancer Res 70:8077–8087

    CAS  PubMed  Google Scholar 

  135. Borel F, Konstantinova P, Jansen PL (2012) Diagnostic and therapeutic potential of miRNA signatures in patients with hepatocellular carcinoma. J Hepatol 56:1371–1383

    CAS  PubMed  Google Scholar 

  136. Liu WH, Yeh SH, Chen PJ (1809) Role of microRNAs in hepatitis B virus replication and pathogenesis. Biochim Biophys Acta 2011:678–685

    Google Scholar 

  137. Zhang X, Zhang E, Ma Z, Pei R, Jiang M, Schlaak JF et al (2011) Modulation of hepatitis B virus replication and hepatocyte differentiation by MicroRNA-1. Hepatology 53:1476–1485

    CAS  PubMed  Google Scholar 

  138. Wang Z, Lin S, Li JJ, Xu Z, Yao H, Zhu X et al (2011) MYC protein inhibits transcription of the microRNA cluster MC-let-7a-1–let-7d via noncanonical E-box. J Biol Chem 286:39703–39714

    CAS  PubMed Central  PubMed  Google Scholar 

  139. Au SL, Wong CC, Lee JM, Fan DN, Tsang FH, Ng IO et al (2012) Enhancer of zeste homolog 2 epigenetically silences multiple tumor suppressor microRNAs to promote liver cancer metastasis. Hepatology 56:622–631

    CAS  PubMed  Google Scholar 

  140. Peng X, Li Y, Walters KA, Rosenzweig ER, Lederer SL, Aicher LD et al (2009) Computational identification of hepatitis C virus associated microRNA-mRNA regulatory modules in human livers. BMC Genomics 10:373

    PubMed Central  PubMed  Google Scholar 

  141. Hou W, Tian Q, Zheng J, Bonkovsky HL (2010) MicroRNA-196 represses Bach1 protein and hepatitis C virus gene expression in human hepatoma cells expressing hepatitis C viral proteins. Hepatology 51:1494–1504

    CAS  PubMed Central  PubMed  Google Scholar 

  142. Shen J, Wang S, Zhang YJ, Kappil MA, Chen WH, Kibriya MG et al (2012) Genome-wide aberrant DNA methylation of microRNA host genes in hepatocellular carcinoma. Epigenetics 7:1230–1237

    CAS  PubMed Central  PubMed  Google Scholar 

  143. Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K et al (2008) Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol 141:672–675

    PubMed  Google Scholar 

  144. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL et al (2008) Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 105:10513–10518

    CAS  PubMed Central  PubMed  Google Scholar 

  145. Chen C-J (2013) Early diagnosis of hepatocellular carcinoma by multiple microRNAs: validity, efficacy, and cost-effectiveness. J Clin Oncol 29:4745–4747

    Google Scholar 

  146. Zhou J, Yu L, Gao X, Hu J, Wang J, Dai Z et al (2011) Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. J Clin Oncol 29:4781–4788

    CAS  PubMed  Google Scholar 

  147. Li LM, Hu ZB, Zhou ZX, Chen X, Liu FY, Zhang JF et al (2010) Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV-positive hepatocarcinoma. Cancer Res 70:9798–9807

    CAS  PubMed  Google Scholar 

  148. Shen J, Wang A, Wang Q, Gurvich I, Siegel AB, Remotti H et al (2013) Exploration of genome-wide circulating microRNA in hepatocellular carcinoma: MiR-483-5p as a potential biomarker. Cancer Epidemiol Biomarkers Prev 22:2364–2373

    CAS  PubMed  Google Scholar 

  149. Zhang SG, Wang X, Yuan Q, Yan Q, Ye H, Che Y, Lin Y, Zhang J, Liu P (2013) Serum miR-483-5p as a potential biomarker to detect hepatocellular carcinoma. Hepatol Int 7:199–207

    Google Scholar 

  150. Abdalla MA, Haj-Ahmad Y (2012) Promising urinary protein biomarkers for the early detection of hepatocellular carcinoma among high-risk hepatitis C virus egyptian patients. J Cancer 3:390–403

    CAS  PubMed Central  PubMed  Google Scholar 

  151. Cortessis VK, Thomas DC, Levine AJ, Breton CV, Mack TM, Siegmund KD et al (2012) Environmental epigenetics: prospects for studying epigenetic mediation of exposure-response relationships. Hum Genet 131:1565–1589

    CAS  PubMed Central  PubMed  Google Scholar 

  152. Pennisi E (2005) Environmental epigenomics meeting. Supplements restore gene function via methylation. Science 310:1761

    PubMed  Google Scholar 

Download references

Acknowledgments

I sincerely thank Dr. Regina M. Santella for her invaluable comments and suggestions; Dr. Chien-Jen Chen for his encouragement and long-term cooperation and Dr. Jing Shen for his bibliographic assistance.

Author information

Authors and Affiliations

  1. Department of Environmental Health Sciences, Mailman School of Public Health and Cancer Center of Columbia University, Room 1608, 630 West 168th Street, New York, NY, 10032, USA

    Yujing Zhang

Authors
  1. Yujing Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yujing Zhang .

Editor information

Editors and Affiliations

  1. National Institutes of Health, Rockville, Maryland, USA

    Mukesh Verma

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer Science+Business Media New York

About this protocol

Cite this protocol

Zhang, Y. (2015). Detection of Epigenetic Aberrations in the Development of Hepatocellular Carcinoma. In: Verma, M. (eds) Cancer Epigenetics. Methods in Molecular Biology, vol 1238. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-1804-1_37

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-1804-1_37

  • Published:

  • Publisher Name: Humana Press, New York, NY

  • Print ISBN: 978-1-4939-1803-4

  • Online ISBN: 978-1-4939-1804-1

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation